MX2022000815A - Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia. - Google Patents

Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia.

Info

Publication number
MX2022000815A
MX2022000815A MX2022000815A MX2022000815A MX2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A
Authority
MX
Mexico
Prior art keywords
antibody
immunotherapy
sting agonist
agonist conjugates
conjugates
Prior art date
Application number
MX2022000815A
Other languages
English (en)
Spanish (es)
Inventor
Zhijian Chen
Lijun Sun
Heping Shi
Chuo Chen
Qi Wei
Jian Qiu
youtong Wu
Original Assignee
Immunesensor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunesensor Therapeutics Inc filed Critical Immunesensor Therapeutics Inc
Publication of MX2022000815A publication Critical patent/MX2022000815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MX2022000815A 2019-07-19 2020-07-20 Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia. MX2022000815A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876590P 2019-07-19 2019-07-19
US202063019212P 2020-05-01 2020-05-01
PCT/US2020/042815 WO2021016204A1 (en) 2019-07-19 2020-07-20 Antibody-sting agonist conjugates and their use in immunotherapy

Publications (1)

Publication Number Publication Date
MX2022000815A true MX2022000815A (es) 2022-05-03

Family

ID=71995149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000815A MX2022000815A (es) 2019-07-19 2020-07-20 Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia.

Country Status (13)

Country Link
US (3) US11033635B2 (cg-RX-API-DMAC7.html)
EP (1) EP3999118A1 (cg-RX-API-DMAC7.html)
JP (1) JP7576779B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054794A (cg-RX-API-DMAC7.html)
CN (2) CN117838878A (cg-RX-API-DMAC7.html)
AU (1) AU2020315802A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000854A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147890A1 (cg-RX-API-DMAC7.html)
IL (1) IL289866A (cg-RX-API-DMAC7.html)
MX (1) MX2022000815A (cg-RX-API-DMAC7.html)
TW (1) TWI877186B (cg-RX-API-DMAC7.html)
WO (1) WO2021016204A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201988B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033635B2 (en) * 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy
US20240218009A1 (en) * 2021-04-21 2024-07-04 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
US20250057967A2 (en) * 2021-06-25 2025-02-20 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
EP4412660A1 (en) * 2021-10-04 2024-08-14 Bolt Biotherapeutics, Inc. Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof
US20250108123A1 (en) * 2021-12-17 2025-04-03 Jacobio Pharmaceuticals Co., Ltd. Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof
EP4653017A1 (en) * 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
IL322523A (en) * 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
CN122180515A (zh) * 2023-06-30 2026-06-09 免疫原公司 包含sting激动剂的组合物和用于治疗神经胶质瘤的使用方法
CN117343111B (zh) * 2023-12-04 2024-02-06 康羽生命科学技术(苏州)有限公司 核苷修饰物n2-异丁酰-2'-甲氧基鸟苷的制备方法
CN120204418A (zh) * 2023-12-27 2025-06-27 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用
WO2026035986A1 (en) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Humanized anti-cdh17 antibodies and use of the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
GB2552041A (en) * 2015-12-07 2018-01-10 Opi Vi - Ip Holdco Llc Compositions of antibody construct-agonist conjugates and methods thereof
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
RU2019122598A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
US11033635B2 (en) 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy

Also Published As

Publication number Publication date
IL289866A (en) 2022-03-01
TWI877186B (zh) 2025-03-21
US12311030B2 (en) 2025-05-27
JP2022541517A (ja) 2022-09-26
WO2021016204A1 (en) 2021-01-28
TW202116358A (zh) 2021-05-01
US20210015941A1 (en) 2021-01-21
KR20220054794A (ko) 2022-05-03
BR112022000854A2 (pt) 2022-03-08
CN114786729A (zh) 2022-07-22
US20210290774A1 (en) 2021-09-23
CN114786729B (zh) 2023-12-19
ZA202201988B (en) 2023-10-25
US11033635B2 (en) 2021-06-15
US11213592B2 (en) 2022-01-04
JP7576779B2 (ja) 2024-11-01
CA3147890A1 (en) 2021-01-28
EP3999118A1 (en) 2022-05-25
CN117838878A (zh) 2024-04-09
AU2020315802A1 (en) 2022-02-24
US20220105198A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
ZA202201988B (en) Antibody-sting agonist conjugates and their use in immunotherapy
MX2024008677A (es) Conjugados de camptotecina.
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
ZA202108534B (en) Antibody drug conjugates
MX2024011292A (es) Conjugados de camptotecina.
MX2021002575A (es) Conjugados de polipeptidos de interleucina-2 y sus usos.
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX370787B (es) Anticuerpos anti-prlr y usos de los mismos.
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
CY1121870T1 (el) Anti-egfrviii αντισωματα και χρησεις αυτων
MX2024002632A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
SG11201907321TA (en) Anti-gprc5d antibody and molecule comprising the antibody
CR20200206A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
ZA202304464B (en) Antibody drug conjugates
MX2019012811A (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion.
MY148763A (en) Anti-5t4 antibodies and uses thereof
BR112015027322A2 (pt) compostos antissenso conjugados e sua utilização
MX2018005289A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll.
PH12022551000A1 (en) Directed conjugation technologies
PH12013501942A1 (en) Antibody-drug conjugates
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
MX2023006596A (es) Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma.
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.